When to Order Imaging for Post-Treatment Surveillance of Bladder Cancer: ACR Appropriateness Decoded
A patient with a history of treated bladder cancer is in your clinic for routine follow-up. They feel well, but you know surveillance is critical for detecting recurrence. The guidelines mention cystoscopy and urine cytology, but what is the role of cross-sectional imaging? Do you order a Computed Tomography (CT) urogram, a standard abdominal CT, or perhaps a Magnetic Resonance Imaging (MRI)? The choice depends heavily on the initial tumor stage and the patient’s current clinical status. Ordering unnecessary imaging can lead to excess radiation and costs, while missing a key study can delay the diagnosis of recurrent or metastatic disease. This guide clarifies the American College of Radiology (ACR) recommendations to help you select the most appropriate study for each patient.
What Does ACR Post-Treatment Surveillance of Bladder Cancer Cover?
This ACR Appropriateness Criteria topic focuses specifically on the role of imaging in the surveillance of patients who have already completed definitive treatment for bladder cancer. The guidance is stratified based on the original tumor type—nonmuscle invasive bladder cancer (NMIBC) versus muscle-invasive bladder cancer (MIBC)—and the presence of clinical signs or symptoms of recurrence. These recommendations are intended to guide routine follow-up imaging to detect local recurrence, upper tract urothelial carcinoma, or distant metastases.
This document does not cover the initial diagnosis or staging of a newly discovered bladder mass. It also does not address imaging for other genitourinary malignancies or for acute complications related to bladder cancer treatment, such as urinary obstruction or abscess, which would be evaluated under different clinical guidelines.
What Imaging Should I Order for Post-Treatment Surveillance of Bladder Cancer? Recommendations by Clinical Scenario
The appropriate imaging for bladder cancer surveillance is determined by the patient’s initial cancer stage and current symptoms. The ACR provides clear guidance for three primary clinical variants.
For a patient with a history of nonmuscle invasive bladder cancer who has no symptoms or risk factors, routine surveillance imaging is Usually Not Appropriate. This includes CT, MRI, and ultrasound. The standard of care for this low-risk group primarily involves regular cystoscopy and urine cytology, as the risk of metastatic disease or upper tract recurrence is low. Cross-sectional imaging is generally reserved for when there is a clinical suspicion of recurrence that cannot be evaluated by endoscopic methods alone.
In contrast, for a patient with nonmuscle invasive bladder cancer who presents with new symptoms (e.g., hematuria, flank pain) or has risk factors for upper tract disease, imaging becomes essential. For this scenario, the ACR rates both MR Urography (MRU) without and with IV contrast and CT Urography (CTU) without and with IV contrast as Usually Appropriate. These studies are optimized to evaluate the entire urothelial tract, including the kidneys, ureters, and bladder, for new or recurrent tumors. A standard CT abdomen and pelvis with IV contrast or MRI abdomen and pelvis without and with IV contrast may also be appropriate to assess for nodal or metastatic disease.
For patients with a history of muscle-invasive bladder cancer, with or without prior cystectomy, surveillance imaging is a cornerstone of follow-up. The ACR rates several studies as Usually Appropriate, reflecting the higher risk of local and distant recurrence. These include CT abdomen and pelvis with IV contrast, CTU without and with IV contrast, and MRU without and with IV contrast. A baseline chest radiograph is also considered Usually Appropriate for pulmonary surveillance. In post-cystectomy patients with a urinary diversion, a fluoroscopy abdomen loopogram is also Usually Appropriate to evaluate the conduit’s integrity and rule out obstruction.
ACR Imaging Recommendations Table
| Clinical Scenario | Top Procedure | ACR Rating | Adult RRL | Pediatric RRL |
|---|---|---|---|---|
| Nonmuscle invasive bladder cancer no symptoms or risk factors. Post-treatment surveillance. | CTU without and with IV contrast | Usually Not Appropriate | ☢ ☢ ☢ ☢ 10-30 mSv | ☢ ☢ ☢ ☢ ☢ 10-30 mSv [ped] |
| Nonmuscle invasive bladder cancer with symptoms or risk factors. Post-treatment surveillance. | MRU without and with IV contrast | Usually Appropriate | O 0 mSv | O 0 mSv [ped] |
| Muscle-invasive bladder cancer with or without cystectomy. Post-treatment surveillance. | CT abdomen and pelvis with IV contrast | Usually Appropriate | ☢ ☢ ☢ 1-10 mSv | ☢ ☢ ☢ ☢ 3-10 mSv [ped] |
Adult vs. Pediatric Post-Treatment Surveillance of Bladder Cancer Imaging: Radiation Dose Tradeoffs
Bladder cancer is exceptionally rare in the pediatric population, but when it occurs, surveillance strategies must be carefully considered to minimize long-term risks from ionizing radiation. The principle of ALARA (As Low As Reasonably Achievable) is paramount. The ACR provides distinct pediatric relative radiation level (RRL) estimates, which are often lower than adult levels for the same study due to differences in patient size and scanner settings. For any scenario requiring cross-sectional imaging in a young patient, there is a strong preference for non-ionizing modalities.
For example, in cases where upper tract evaluation is necessary, MR Urography (RRL O 0 mSv) is often preferred over CT Urography (Pediatric RRL ☢ ☢ ☢ ☢ ☢ 10-30 mSv) to avoid radiation exposure, provided the patient can tolerate the scan and has no contraindications to MRI or gadolinium-based contrast agents. When CT is unavoidable, protocols should be specifically tailored to pediatric patients to reduce the radiation dose while maintaining diagnostic quality.
Imaging Protocol Details for Post-Treatment Surveillance of Bladder Cancer
Once you’ve decided on the right study, the specific imaging protocol is critical for obtaining diagnostic-quality images. Key considerations include the phases of contrast enhancement for CT, the specific sequences for MRI, and patient preparation. Our detailed protocol guides cover technique, contrast administration, and interpretation principles for the studies recommended in these guidelines.
Tools to Help You Order the Right Study
Navigating imaging guidelines during a busy clinical day can be challenging. GigHz offers several tools designed to streamline the process of selecting the correct study and communicating with patients about the benefits and risks.
For clinical scenarios beyond bladder cancer surveillance, the ACR Appropriateness Criteria Lookup provides a quick way to find evidence-based recommendations for hundreds of clinical presentations. It helps ensure you are ordering the most suitable test based on national guidelines.
To understand the technical details of the recommended studies, the Imaging Protocol Library offers in-depth guides on how specific CT and MRI scans are performed. This can be useful when communicating with radiology departments or for trainees learning the nuances of different imaging techniques.
When discussing studies that involve ionizing radiation, the Radiation Dose Calculator is a valuable resource. It helps estimate cumulative radiation exposure for patients and provides context for discussions about the risks and benefits of necessary medical imaging.
Why is routine imaging “Usually Not Appropriate” for asymptomatic NMIBC surveillance?
For patients with nonmuscle invasive bladder cancer (NMIBC) without symptoms or specific risk factors, the risk of developing upper tract urothelial carcinoma or distant metastases is very low. The primary methods for surveillance in this group are office cystoscopy and urine cytology, which are highly effective for detecting local bladder recurrence. The low yield of cross-sectional imaging, combined with the costs and potential radiation exposure, makes it an inappropriate tool for routine screening in this specific patient population.
What is the difference between a CT Urogram (CTU) and a standard CT Abdomen/Pelvis?
A standard CT of the abdomen and pelvis is typically performed with a single post-contrast phase (portal venous phase) to evaluate solid organs, bowel, and vasculature. A CT Urogram is a specialized protocol designed to visualize the entire urinary tract. It includes non-contrast images to detect stones, a nephrographic phase to evaluate the renal parenchyma, and a delayed excretory phase where contrast fills the renal calyces, ureters, and bladder. This delayed phase is essential for detecting urothelial tumors, which appear as filling defects.
When is MRI or MR Urography a better choice than CT for bladder cancer surveillance?
MRI/MRU is an excellent alternative to CTU, particularly in patients who require frequent imaging, are young, or have contraindications to iodinated contrast media (e.g., severe allergy or renal impairment, though gadolinium has its own considerations). MRI offers superior soft-tissue contrast for evaluating the bladder wall and perivesical tissues for local recurrence without using ionizing radiation. It is considered “Usually Appropriate” and equivalent to CTU for symptomatic NMIBC and for MIBC surveillance.
What are the key risk factors that warrant imaging in a patient with NMIBC?
Certain features of the initial nonmuscle invasive tumor increase the risk of subsequent upper tract disease, prompting the need for surveillance imaging even with NMIBC. These risk factors include high-grade tumors (including carcinoma in situ), large or multifocal tumors, tumors located in the trigone, or recurrent NMIBC after initial treatment. New clinical symptoms like gross hematuria or flank pain are also strong indications for imaging.
What is a loopogram and why is it used after a cystectomy?
A loopogram, or retrograde ureterography, is a fluoroscopic study performed in patients who have had a radical cystectomy and urinary diversion (e.g., an ileal conduit). A catheter is placed into the stoma, and contrast is injected to opacify the conduit and reflux into the ureters. It is used to evaluate the anatomy of the diversion, check for leaks, strictures, or obstructions, and can sometimes identify filling defects suggestive of recurrent tumor within the upper tracts or the conduit itself. It is rated as “Usually Appropriate” for surveillance in this patient population.
Frequently Asked Questions
Why is routine imaging “Usually Not Appropriate” for asymptomatic NMIBC surveillance?
For patients with nonmuscle invasive bladder cancer (NMIBC) without symptoms or specific risk factors, the risk of developing upper tract urothelial carcinoma or distant metastases is very low. The primary methods for surveillance in this group are office cystoscopy and urine cytology, which are highly effective for detecting local bladder recurrence. The low yield of cross-sectional imaging, combined with the costs and potential radiation exposure, makes it an inappropriate tool for routine screening in this specific patient population.
What is the difference between a CT Urogram (CTU) and a standard CT Abdomen/Pelvis?
A standard CT of the abdomen and pelvis is typically performed with a single post-contrast phase (portal venous phase) to evaluate solid organs, bowel, and vasculature. A CT Urogram is a specialized protocol designed to visualize the entire urinary tract. It includes non-contrast images to detect stones, a nephrographic phase to evaluate the renal parenchyma, and a delayed excretory phase where contrast fills the renal calyces, ureters, and bladder. This delayed phase is essential for detecting urothelial tumors, which appear as filling defects.
When is MRI or MR Urography a better choice than CT for bladder cancer surveillance?
MRI/MRU is an excellent alternative to CTU, particularly in patients who require frequent imaging, are young, or have contraindications to iodinated contrast media (e.g., severe allergy or renal impairment, though gadolinium has its own considerations). MRI offers superior soft-tissue contrast for evaluating the bladder wall and perivesical tissues for local recurrence without using ionizing radiation. It is considered “Usually Appropriate” and equivalent to CTU for symptomatic NMIBC and for MIBC surveillance.
What are the key risk factors that warrant imaging in a patient with NMIBC?
Certain features of the initial nonmuscle invasive tumor increase the risk of subsequent upper tract disease, prompting the need for surveillance imaging even with NMIBC. These risk factors include high-grade tumors (including carcinoma in situ), large or multifocal tumors, tumors located in the trigone, or recurrent NMIBC after initial treatment. New clinical symptoms like gross hematuria or flank pain are also strong indications for imaging.
What is a loopogram and why is it used after a cystectomy?
A loopogram, or retrograde ureterography, is a fluoroscopic study performed in patients who have had a radical cystectomy and urinary diversion (e.g., an ileal conduit). A catheter is placed into the stoma, and contrast is injected to opacify the conduit and reflux into the ureters. It is used to evaluate the anatomy of the diversion, check for leaks, strictures, or obstructions, and can sometimes identify filling defects suggestive of recurrent tumor within the upper tracts or the conduit itself. It is rated as “Usually Appropriate” for surveillance in this patient population.
Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 21, 2026